Ophthotech promotes David R. Guyer to executive chairman
Staff Writer |
New York, N.Y., USA - April 26, 2017, New York, N.Y., USA - Ophthotech Corporation, a biopharmaceutical company, announced that David R. Guyer, a co-founder, chief executive officer and chairman of the board of Ophthotech will transition to executive chairman, effective July 1, 2017.
Article continues below
Dr. Guyer is a co-founder of Ophthotech and has served as Chairman of the Board since the Company’s inception in 2007 and as the Chief Executive Officer of Ophthotech since April 2013.
Previously Dr. Guyer worked as a venture capitalist and Partner at SV Life Sciences.
He has significant medical, drug development and commercial experience in ophthalmology.
Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and a member of the Board of Directors of Eyetech Pharmaceuticals.
Dr. Guyer received his BS degree from Yale College summa cum laude and his MD from Johns Hopkins Medical School.
He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
Concurrent with this transition, Ophthotech’s Board of Directors appointed Glenn P. Sblendorio, the Company’s President and Chief Financial Officer, as Chief Executive Officer of the Company, also effective July 1, 2017.
Mr. Sblendorio joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer.
Mr. Sblendorio also served as a member of the Board of Directors of Ophthotech from 2013 to 2016.
Prior to joining Ophthotech, Mr. Sblendorio served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016.
Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals.
From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company.
Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions.
He currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals.
Mr. Sblendorio received his BBA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.
The Company also announced the promotion of David F. Carroll to Chief Financial Officer and Treasurer.
Mr. Carroll was previously Senior Vice President, Finance, of the Company.
Mr. Carroll joined Ophthotech in 2016 and has more than 25 years of experience in the life sciences industry.
Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller and most recently, Senior Vice President, Chief Accounting Officer.
Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb. ■